<SEC-DOCUMENT>0001178913-15-003782.txt : 20151223
<SEC-HEADER>0001178913-15-003782.hdr.sgml : 20151223
<ACCEPTANCE-DATETIME>20151223060123
ACCESSION NUMBER:		0001178913-15-003782
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20151223
FILED AS OF DATE:		20151223
DATE AS OF CHANGE:		20151223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAMADA LTD
		CENTRAL INDEX KEY:			0001567529
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35948
		FILM NUMBER:		151304175

	BUSINESS ADDRESS:	
		STREET 1:		7 SAPIR ST. WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			74140
		BUSINESS PHONE:		97289406472

	MAIL ADDRESS:	
		STREET 1:		7 SAPIR ST. WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			74140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk1517759.htm
<DESCRIPTION>6-K
<TEXT>
<html>
<head>
    <title>zk1517759.htm</title>
    <!--Licensed to: ZKG-->
    <!--Document Created using EDGARizer 2020 5.5.2.0-->
    <!--Copyright 1995 - 2015 Summit Financial Printing. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">FORM 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Report of Foreign Private Issuer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Rule 13a-16 or 15d-16</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the Month of December, 2015</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission File Number 001-35948</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold">Kamada Ltd.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">7 Sapir St.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Kiryat Weizmann Science Park</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">P.O Box 4081</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Ness Ziona 74140</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Israel</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Address of principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form 20-F&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font>&#160;&#160;&#160;Form 40-F <font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes <font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;No <font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-____</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">This Form 6-K is being incorporated by reference into the Registrant&#8217;s Form S-8 Registration Statement File No. 333-192720.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following exhibit is attached:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: left; WIDTH: 45pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">99.1&#160;</font></div>
</td>
<td align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">News Release: Kamada&#8217;s Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Phase 2/3 Clinical Trial as a Post-Exposure Treatment</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURE</font></div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -9pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div>&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: December 23, 2015</font></div>
</td>
<td align="left" colspan="2" valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">KAMADA LTD.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td align="left" valign="top" width="17%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></td>
<td align="left" valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">/s/ Gil Efron</font></font></div>
</td>
<td align="left" valign="top" width="17%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gil Efron</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deputy Chief Executive Officer and Chief Financial Officer</font></div>
</td>
<td align="left" valign="top" width="17%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">EXHIBIT INDEX</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">EXHIBIT NO.</font></font></div>
</td>
<td valign="top" width="91%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">DESCRIPTION</font></font></div>
</td>
</tr><tr>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="9%" style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">News Release: Kamada&#8217;s Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal</font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Phase 2/3 Clinical Trial as a Post-Exposure Treatment</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
    <title>exhibit_99-1.htm</title>
    <!--Licensed to: ZKG-->
    <!--Document Created using EDGARizer 2020 5.5.2.0-->
    <!--Copyright 1995 - 2015 Summit Financial Printing. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">EXHIBIT 99.1</font></div>



<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="50%"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 26pt; FONT-WEIGHT: bold">News Release</font></font></div>
</td>
<td width="50%" style="TEXT-ALIGN: right"><img src="kamada.jpg" alt=""></td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt">Kamada&#8217;s Human Rabies Immune Globulin Successfully </font>Meets Primary Endpoint </font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt">in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Strategic agreement with Kedrion for clinical development and marketing</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Plans to file a BLA with the FDA in mid-2016</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">NESS ZIONA, Israel (December 23, 2015) &#8211; Kamada Ltd. (NASDAQ and TASE: KMDA), </font>a plasma-derived protein therapeutics company focused on orphan indications, reports that the pivotal Phase 2/3 clinical trial with the Company&#8217;s human rabies immune globulin (IgG or KamRAB&#8482; or KedRAB&#8482;) therapy as a post-exposure treatment for rabies successfully met the trial&#8217;s primary endpoint of non-inferiority when measured against an IgG reference product.&#160;&#160;The Company expects to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) in mid-2016.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">KamRAB is the brand name for Kamada's human rabies immune globulin currently marketed for this indication in 10 countries worldwide.&#160;&#160;Kamada has a strategic agreement with Kedrion S.p.A for the clinical development and marketing of its IgG product, which will be branded as KedRAB in the U.S., subject to receiving marketing approval from the FDA.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Phase 2/3 clinical trial was a prospective, randomized, double-blind, non-inferiority study of 118 healthy subjects.&#160;&#160;The study evaluated pharmacokinetic (PK) parameters of anti-rabies IgG levels in serum at different time points and assessed whether Kamada&#8217;s IgG interferes with the development of self-active antibodies. In addition, safety and tolerability were assessed.&#160;&#160;The trial&#8217;s primary end point measured the anti-rabies titer on day 14 as well as on additional time points for secondary end points, following drug infusion and infusion of an active vaccine as recommended by the standard-of-care.&#160;&#160;The primary endpoint was designed to determine non-inferiority with a <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font>10% margin. Detailed information about this study is available at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.clinicaltrials.gov</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Top-line results showed that the primary endpoint of non-inferiority was met with a difference of -1.8% between the two therapies with variability between -8.2% and 3.1% (90% Confidence limit).&#160;&#160;Results showed that Kamada&#8217;s IgG was safe and well tolerated with no drug-related Serious Adverse Events (SAEs) experienced.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;The post-prophylaxis treatment has proven critical for this fatal rabies disease. We are delighted to report the positive data, which show our IgG product achieved its primary endpoint of non-inferiority in this pivotal trial and demonstrated that our IgG product doesn&#8217;t interfere with the development of self-active antibodies,&#8221; commented Dr. Eran Schenker, V.P.- Medical Director of Kamada.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;Since 2003 we have marketed KamRAB in 10 countries outside the U.S. and we have sold more than one million vials to date, which provides significant experience with this product.&#160;&#160;We are confident our product will provide a much-needed, high-quality source of IgG for people who are at risk of being exposed to rabies.&#160;&#160;Consequently, we have confidence that our product will be competitive with the current reference IgG product in providing the needed protection,&#8221; said Amir London, Chief Executive Officer of Kamada. &#8220;The WHO estimates that approximately 10 million people worldwide require medical treatment against rabies each year after being exposed to an animal suspected of rabies infection.&#160;&#160;We believe that a competitive product in the U.S. will provide diversity of supply in a market with ample room for a new product entry while improving Kamada profitability with higher margins expected in the US compared to rest of the world countries. We plan on leveraging the U.S. trial and future marketing approval to expand our global market leadership with this critical medical treatment.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;We are very excited about the commercial potential for KedRAB in the U.S., where there are approximately 40,000 post<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font>exposure prophylaxis treatments administrated each year, representing a more than $100 million annual market opportunity. With one predominant rabies prophylaxis provider in the U.S., we anticipate that healthcare professionals will want to diversify their source of supply<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">,</font> particularly if a competing high-quality product, such as KedRAB, is approved for use.&#160;&#160;We look forward to a favorable regulatory outcome and, in time, a successful product launch,&#8221; stated Larry Guiheen, Kedrion&#8217;s Chief Commercial Officer.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About KamRAB/KedRAB</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Rabies is a preventable viral disease of mammals most often transmitted through exposure to a rabid animal. KamRAB/KedRAB is a prophylactic treatment against rabies infection that is administered to patients after exposure to an animal suspected of being infected with rabies. KamRAB/KedRAB is a protein therapeutic derived from hyper-immune plasma, which is plasma that contains high levels of antibodies from donors that have been previously exposed to rabies. KamRAB/KedRAB is administered via a one-time injection, with the precise dosage being a function of the patient&#8217;s weight.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Kedrion S.p.A.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Kedrion is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and preventing serious diseases, disorders and conditions such as hemophilia, immune system deficiencies and hemolytic disease of the fetus and newborn. Kedrion places a high value on not only the welfare of those who benefit from its products, but also on the people and communities it serves.&#160;Headquartered in Italy, Kedrion has a market presence in over 100 countries. In the field of plasma derivatives, it is the world&#8217;s fifth most important player and Italy&#8217;s first. Additional information about Kedrion can be found at www.kedrion.com.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Kamada</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline.&#160;&#160;The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.&#160;&#160;&#160;AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company&#8217;s flagship product is Glassia&#174;, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia in the U.S. through a strategic partnership with Baxalta.&#160;&#160;In addition to Glassia, Kamada has a product line of nine other injectable pharmaceutical products that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America, Eastern Europe and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that completed pivotal Phase 2/3 clinical trials in Europe and is in Phase 2 clinical trials in the U.S. and its intravenous AAT to treat type-1 diabetes, GVHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing 10 complementary products in Israel that are manufactured by third parties.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cautionary Note Regarding Forward-Looking Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.&#160;&#160;Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, timing and results of clinical trials and EMA and U.S. FDA authorizations.&#160;&#160;Forward-looking statements are based on Kamada&#8217;s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions.&#160;&#160;Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the U.S. FDA or the EMA approval process, additional competition in the AATD market or further regulatory delays.&#160;&#160;The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contacts:</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gil Efron</font></div>
</td>
<td valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Anne Marie Fields</font></div>
</td>
</tr><tr>
<td valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CFO</font></div>
</td>
<td valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">LHA</font></div>
</td>
</tr><tr>
<td valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">ir@kamada.com</font></font></div>
</td>
<td valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">212-838-3777</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">afields@lhai.com</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>kamada.jpg
<TEXT>
begin 644 kamada.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M!..,$<U]0^!\=%?O:E.+[.6OX)GQD_$;+KWI4JLX]U#1VWM=K8^_?^$AO/\
MGM_XXO\ A1_PD-Y_SV_\<7_"OB[P1_P4,\0:5,J:YIUMJ4'&YX_W<O\ A7TC
M\(_CUX=^,VGB72KM5NE&9+67Y98_P[CW%>1F7#N.P*YZT/=[K5?\#YGLY-Q?
ME>9R]GAZEI_RRT?RZ/Y-GH'_  D-Y_SV_P#'%_PH_P"$AO/^>W_CB_X52H)
MZD#ZUX9],7?^$AO/^>W_ (XO^%'_  D-Y_SV_P#'%_PJEN'JOYTH!)P!DT 7
M/^$AO/\ GM_XXO\ A1_PD-Y_SV_\<7_"J9!!P>#Z=Z0G')P * +O_"0WG_/;
M_P <7_"C_A(;S_GM_P".+_A5%)%E7<CHZ^JD$?I2YH"Y=_X2&\_Y[?\ CB_X
M4?\ "0WG_/;_ ,<7_"J60>A!_&B@"[_PD-Y_SV_\<7_"C_A(;S_GM_XXO^%4
MJ,@=2!^- %W_ (2&\_Y[?^.+_A1_PD-Y_P ]O_'%_P *I4DDJ1+N=T1>F6(
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M %?7+/QP"K375A<E+;2X,Y9YP 06*YP#ZBOCKX$?M07O[,NL?%RYTVRGFO\
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MP;IM.:_1WX2:NVO_  5T6]9B[7&G!B?P(_I7YQ*N]E7&=QQ7Z Z-\--1UWX
M:!H5EK%UX?FCM$62:! SE2#E>>G6OF..XTW3H*;M[SU[*VNVO8^V\+9U8UL3
M*$>;W%IW=]-].Y\B?\$WOAII'Q=\9_'3P_KEI'>:??NJ.K#)4_:),,I[$'N*
MR] UGQ5_P2O^//\ 9NI&YU3X>:]*6C9260(3]X?W9%[COBOHWX(_\$^8/@#X
MRN-:\/\ C+6HI[]@;U'162[&<X;\2:]:^./P+T#]H'P!=>'_ !!;":WG7]W*
MN!) _9U/;FN/&\581YA43?M<+645*-FFFHJ/,K]5:ZMT/8R[@K'1RNDXKV.,
MH.3A*Z:DI2<N65MXN]FGL_(V="^(.D>(_ T?B2RO(+G2)+<W0G1P5V 9//J*
M^</V=?V??#'[4$'B+XC>+=-75Y/$NIRG3FD=AY=K&Q1 ,>H -:/AK_@G4W@_
MP+>^&=-^(?B>UT+4 5FM%*E"#U ],^U>A_LZ?LV7/[.^E6^E6GBC4=3T.T5E
MALKB-=L6?0CWKP/;8/!4*WU#$/GDU9VE%\BNVK]V[>6A]/[#'YAB</\ VGA%
M[."?,N:,ESNR3MU25[=;O;0^:?\ @I%^R'X?^$OPCL/&/@K2UTJ]T&]22X>,
MDX7(VMSW#8KZL_9=^*T7QK^ _ASQ#$P>2[M52;G)$BC#9]#D9_&JO[2'[/S_
M +17A4Z'/KU[I.DSILNH($#?:?FR,D],8KAOA)^PW>? _P /7&D^'/B!X@LM
M.N,MY.U2L;G^)<]#6]?,L/CLHIX?&5OWT)-IM2?NO=-V?75'/ALHQ66Y[5Q.
M P_^SU()22<5[\=FE=:6T>VI>^%5_'JG[<?Q+,<D+K:Z9:0%0V6)VH3QZ \5
M\O\ [8?AZ[_8=_;-T;XDZ+$RZ/KDOVB:).%9A@2QD=,$8('K7T9\._V"YOAE
M\1+WQ3IWCW7VU?4_^/V655?[4,YPP^M>@_M'_LVZ1^TO\/K;0=:D9!:SQW$=
MPJ@N&4C(^C#(_&NK!YU@\'F$)*?M*$X*G-6:T44GH_-71Q9AP_F&895.+I^R
MQ$*DJM-\R>KDY)77D[.^ESF?V,-"O/$NE:U\1]9A9-7\=7/GPH_W[:S7_51^
MW'/'K7SS^SXX'_!5OQD"0"TMR .YX-?9_B#P%+-\/X=!T/4I] %JD<,%Q H9
MXD08V@'U&*\"T+_@FC:^&_B8_C&S\<^(8O$<DS3O>84N[-G<3]036669OA']
M<GB*G)[6#A%6;LM.7;HDDNYMG&1XY?4*>%I>T]A-5)RYDN9Z\UK]6VWV/1_V
MU_B=+\,?@%J;V<C)JNM,NEV.W[QEE.W/X U@?#W_ ()[_#G0O ^D6FJ>'8+O
M4K>UC2ZF:1LRRA1N;@]SFJWQ7_8<O/C1>:?-KWC_ %ZX72I!-:QHBJD<@(._
M'<\5[+\/O#&H>$M!6TU+6;C7+A3_ ,?,R!7(]#BO-GCH83 PI8&N^=R;G;FC
M?91UTNDK_-GKT\NGCLRJ5\RPR]FHJ,.;EE;5N3M=V;=ODCX0^(WAVR_8*_X*
M$^&]3TF!K+PKXB6.-H@25(D^1U^@8@_A7W5\4)%G^&&MR1L'1["1E8<@@H>:
M\<_:,_8%L_VFO%T>J:_XIU4)9LQLK>)%"VBDYV@]^>]=')^S%K3_  O3PL?'
M^N-:@-&T[(IE:(J%$>?08/YUZ&:8_!8ZGA*TZW[Z"49MJ6J3NG>VK2T9Y62Y
M9F&6U<;0IT/W%23E32E'1M6:M?1-ZKLCPG_@BHP/PT\<*"-W]JQ''?&QN:^N
M/B;\4-%^#O@Z]U_7KV&RL;",R,78!I"!PJCJ23Q@5X%\+/\ @FY'\%+J>;PM
MX_\ $FCM=?ZX0[=LOU!KL(?V&_#WB+48+WQGK/B+QM<6YW+%J-T/LV<Y_P!6
MH'\ZG/J^5XW,ZF.=9N$FGRJ+YM$E;6RZ;W^1?#&&SG+LFI9:L.E4@FN9S7+J
MV[Z7D[7VMKW/!?\ @GI\*]6^,/[1WB3XRZK:36VF7$LJ:7YRD--O/4 ]0%QS
M7J'B[P5I'[6/[7]_I6L0+J7AOP!I_EO&&(1KR0@D''=1FO=O$/@;[3X'?1-#
MNCX=55"0RVL8!@4=E%>2_!O]B:X^"/BR_P!7TGQQK4LVKW N-06X17%VP.23
M[D<5=7/J6)K5<;*?LYJ*A3BDWRK1;I;VNK]WT(H\-5L'AZ&71I^VIN;J5I-Q
M7-)W=N5O5<UG;LNK,GX_?\$]? >N?!WQ!!X?T""RUH6;R6<P=B4=1D=3[5SO
M_!)+XR2>,O@K>^%+Z1SJ/A6XV(KGYS"W] >*^F/B!X8O/&'AB>PL=5GT:>?C
M[3"H9U&.0 ?6O _A7_P3DM_@UXVFU_0?&VO6=]=G-UM5=MR-V2K#TS6>%S>E
MB<JK8/,:S<G)2@WS2::WN]=&C3&9%7P>=X?'Y3ATH*,HU$G&*:>UEI=IZ^A]
M+44D:E(D5F+,H )]3CK2U\8?H*.THHHH YCQ#_R&)O\ @/\ Z"*XCXW_  OM
M?C3\)=?\+7H4P:S:/ "W17(^5OP.#7;^(?\ D,3?\!_]!%4JTI594YJI!V::
M:]49UJ4*L)4ZBNI)I^C/YVOB'\.-1^$7Q)U3PUJT,D%_H]T]M('&"P5L!OH1
M@_C7TO\ L92#X7_!_P >?$"0,EQ;VG]BZ8PX83SKM9E/LC9KZ\_X*B?\$XF_
M:(MCXY\(0I'XMTV/_2K51@:G&!V_VQV]:^-?@@WAK4/!4G@GXA>*O$7A"/2K
MUIQ9Q:<KIYF,$OD;MW;GM7]%4.(:.=97&<7[R<?:12;:UN[))MIV^YG\U5^&
MZ^29M*G->ZU+V<FTD[JRNVTDXWV[H7X">.[CX>?$_1=>BD*S6-TLKOG!()^;
M]":^W/V\;#3K'X7> GTI0MC?7,]['C'_ "V7S#^K5\XZ)\)O@=&RF+XHZY(?
M?2@/Z5ZM<2?#WQ?X;TK2;WXIZY?6&CY%I')IP_=9&/3TKR,UJ4ZV-H8R$9KD
MO=<D]59VZ=&W][-LMIU:&78G U)4W[2W*_:4]&FF_M=4E]R/._"?B2;P?XFL
M-4MR1-83I.H'&=I!Q^.*[#]I30X;#XBMJ5HJBQU^!=0AVC"C>/F'YYK3/P]^
M%8!/_">:J?\ MP'^%97B+3&^(NO:1X<\+WNI^(8+)#%;M/ $,8)YQC^'ZU:Q
M,*F(C6BG%)-2<HN*MONTEHU^+/)>#JTL)/#3<9.4HN*C*,GS;/1-O5/[TAO[
M-_PKG^+'Q4TZQ6,M9V\@N+IB/E$:G)'XXQ7W;\1_B-I7P:\%2:SJPO!IEELC
M<VT!F=0<*/E':N7_ &:O@':_ SP>(7*3ZO>X>[GQGG^X/8?TJ#]LH27?[/&N
MVEO;WMW<W@2..*UB:20G<"2 H)&!WK\WSK,Z>:YI3I+^$FHKI=-ZO^NB/V7A
MG)*N1Y+5KR5JTHN3ZV:7NQ\_/S9T7B;XX:'X1_X1X7J:HI\42+%8".T9RS%=
MP#<_+QZUL^&/%T7B:SN)S;7>GK;W,EMMNT\HN4;&Y<GE3U!KYX\>_#^'PQJO
MPJU*WN_&6I1Q7:2W*7$D]REJ@CP6*;?D(/K7$^*?$6NBRM=*WZ_<M<ZQK12.
MY2?<D#M(;>; &\A05*G&!@5E2R"C6A'V,M7>[?DY=/1+KU.NKQ/B,/4G[>":
M5K)>:AN_63V6R/J:V^+ME<?%VY\'F"1+JVLDOC.S 1,K$@ >_!J[\0_B=I/P
MRL+:;4WG:2^F%O:V]O&99[F0_P *J.OOZ5\AVFAV_BK4+C5-.N?%6I06?AJ)
M(;](IU>:Y25MRYVY)![5['\7?#^NWL_PO\<6EG>:LGAD[]2LPA$P26'8TH4\
MEE/..M3B,DP].M3@Y63333T]Y1NEKMS/378O"\18JKAZLU"[3336MHN5F[+?
ME5WIN>C>"/CCI'C+Q1<Z$\5]I.N6L8F-E?0F%Y(ST=,\,/7'2NR\U22 RY')
MY'%?+_Q!UZU_:?\ BG?ZIX2EN4F\$Z#>P3/AK:\>ZDC8QQA&P^ V.2,9K#'B
M_P 3-K=]?0Z;XNDM;CPYI]O+&R2Q[[E6<3,.,CMG')J9</JHDX/DE9-Q>Z;>
MW3=:HJ'%,J;:G'VD>9J,X[226KLK[/W7;1[KL?2_B;XG6OAGQOX=T22WFF?Q
M(TR03QD&-#%$TA!]R%-:/AOQ?;>(]-M[@)-9/<!BL%THBFPK8)VD]/\ &OD_
MX9:MK.FWGA)-:T[Q&(])UW5I"XM9G-O;303+"58KG&64#N*U?A?X+O-=UOX?
MS^(4\5 3Z?J-C<R@S(T,IG!B+\<?*<Y/'%7B.'Z5.-G/9/5:W:YWHK]HK[UW
M,\+Q16JSO&%^9JR>ED_9K5V[RETZ/L?5LMRD43/N#! 6PO).*\OLOVPO!VI,
MRPG6$=IKFTA:XL6ABGN( Q>%7)QN^4X'>N?_ &5=#UV!]=N]<O9[NVT1Y=+L
M9/-,@O4#LWG''!;&%_"N-^"_PKM/%'@?Q+JFLVVN)=:!K6K:AIUI+#)'$S3&
M39*$(^<E6XK"CE>%INJJ\G+D<4G'^\G^MK]M3IKYSC:L:,L-!0YU)M2[1:OK
MZ<UM[V70^A_AGX^M_B;X(L-;MXGMH[]"XAD8%X\,1@X^E;@N(RNX21E?7<,5
M\<^$+/4/A[X<L9].M_&+SS^'[@WELL<Z_O?.)0#(PK8)Z<XJD;77=;T.UTJZ
MB\7Z=93^)89G%I]HXM6C.X!B-VW)[UT5.&X2J2<*EHW=M-;7]=?U.2EQ=4C2
MA&I2O.ROKHW9>5E?KV>FI]I^?&2 )(\GI\PH\^/86\Q-HX)W# _&OCGXJ^#-
M0TOQ!XRM],NO'!%E=:5%HK1O</N02)]H.['.$+<U?U.^U32O#GB31[.S\67E
MG/KDS6*RBX!\@V\>TE\9(\S?@>N<UDN'(RC&4*M[VZ6T:B^_][[T^QT2XLE&
M<HSHVM?K?5.2[?W;^C7<^MVGC3;ND1=WW<L!GZ>M!N(P6!DC!7J-PR/K7R?\
M,-3UG5++P]8^--(\8W"OHMK!92P^8ABNX]OF%R!PQ8?>;J,UF^'?"7C'Q'I'
MBE+^Z\5IXEMH+L?9OL_EPN,@QD3?QD*!C'.<TGPXHN2G52M;6UT[NUU9[+K>
MUF-<62E&,H4&^:^E[-65[.ZW=[JU[J[/K^XOH+2)Y)9HHD099F< +5#3_%<.
MH^([W3DAN5-C&DK7#)B"0.,@*W<COZ5\D:C;:WXXTWQ%]HMO%DEJ^DZ>0ACF
MC:2:-CYNT8SGU]:V-=NO$/A_Q!XA7PW9^)[C0!::9(8'27S3 H43K&6'WL]0
M.2,U:X<BKQ=1<WW)?#UOO[ST\C-\62=IJD^7[V_CZ6V]U:^:T/K'[1'L#>9'
MM8X#;A@_C7.^$/B3;^+/$OB73!;RVDOAFYBMIGE("RF1"X8>V!7S%\=;G4I_
M!YM/!VB^-((;N%KJU:=YCLEW#[J@<$8/#8%7O%VIZOK1\8SVBZY87&HWUA>*
M[:=,T=PL=N5=7 7)&[CCFBEP[%T^:4_BV[JTHK5)O=-Z>05N*I*KRQA\._:5
MXS=DVELU'7S/K-6#J"I# ]".0:*Y'X W-Y>?!/PQ+J%G/I][)8J9K:9F:2%M
MS<$MSTP>><&NNKYJO2]G4E3O>S:^YV/K\-6]K2A5M;F2?WJYVE%%%9&QSNNV
M4\VJRLD,KJ<8(0D'Y15-M-NN,6\__?LUUU% '*6>G2K.#+:W#)_US/6O!OVI
M_P!@'P[^T1<27\FDK9ZP1A;VVC\N0^FX8YKZDHKJP>-KX6HJN'FXR75')C,#
MA\73='$P4HOHT?E?K_\ P2B^(OA>\)TJ.+5;=3P65HFQ].<U=T#]@/XH6959
M/#\BGU^;'\J_4.BOK(\?YIR<LW&7FUK^#2/AZWACDTYN45*-^BEI^*;_ !/@
M+P=_P3W\67]PC:O$]I$#\RQH68_CVKZ=^!_P#L?@[I9AMM,5'D \R0Q%Y9/J
M<5[!17A9CG^.QJY:\_=[+1?\'YGT&3\*99EKY\+3][^9ZO[WM\K''S:?<&5B
MEI<!"> 4/^%-&GW8.1;7 /\ US/^%=E17C'T9QO]GW8SBVN.?^F9_P *PO%?
MPDT[QMJ-M>:GI,]Q=6:,D,HWHZ*W49&.#FO3Z*NG4E"7-!V?D9U:4*D>6HDU
MV>IP.@^$%\+Z1!8:?ITMK:6XQ'&D;86KG]G777[-<9_ZYG_"NRHJ92;=WJRH
MQ44HQ5DCRH_!/1O^%@IXJ703'X@1/+^UHCHSKC&& X;\:Z/^S[O_ )]KC_OA
MO\*[*BKJ59SMSMNRLK]%V]"*5&G3O[.*5W=V5KON_/S..^P79ZVUS_WPW^%1
M7FBW%]9S026USY<Z&-\(P.",'FNVHJ$^IHU?1GG?A/P%#X'T"WTS3-.FMK*V
M!V($8XSR3D]236E_9]V>MM<'_@!_PKLJ*<YRDW*3NV*$(PBH05DM$CC?[/N_
M^?:X_P"^&_PH_L^[_P"?:X_[X;_"NRHJ;%W.-_L^[_Y]KC_OAO\ "C^S[O\
MY]KC_OAO\*[*B@+G&_V?=_\ /M<?]\'_  H_L^[_ .?:X_[X/^%=E10(XW^S
M[O\ Y]KC_OAO\*/[/N_^?:X_[X;_  KLJ*!W.-_L^[_Y]KC_ +X;_"C[!=_\
L^UQ_WPW^%=E1185SD5TZY*C-O.#_ +AI?[-N?^?>?_O@UUM% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
